Adverse Events of Special Interest Incorrectly Referred to As Serious Adverse Events of Special Interest in the Article by Chatham et al (Arthritis Rheumatol, May 2021)

In the article by Chatham et al in the May 2021 issue of Arthritis & Rheumatology (Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study [pages 816–825]), the term “serious adverse events of special interest” or “serious AEs of special interest” was inadvertently used in place of the term “adverse events of special interest” or “AEs of special interest” in several instances. The first three sentences under the heading Safety and Efficacy Assessments on page 818 should have read as follows: “Safety and tolerability of anifrolumab were assessed by monitoring AEs, serious AEs, AEs of special interest, clinical laboratory tests, and immunogenicity throughout the study. Nonserious AEs were recorded at each monthly visit only during the first year of the study. SAEs and AEs of special interest were recorded at each visit throughout the 3‐year period.” The first sentence of the second paragraph under the heading Safety on page 821 should have read as follows: “All SAEs and AEs of special interest throughout the 3‐year open‐label extension and 1‐year RCT are shown in Table 3.” The first sentence of the third paragraph of the Discussion on page 823 should have read as follows: “Safety profiles of AEs, serious AEs, and AEs of special interest in the open‐label extension were consistent with previous observations (13).” The title of Table 3 should have read as follows: “All serious events and adverse events of special interest during the 3‐year open‐label extension and during the 1‐year RCT” and the third main heading in the left column of the table body (11th row from the bottom) should have read “Patients with ≥1 adverse event of special interest, no. (%).”